Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Pain
Published in: Molecular Pain 1/2011

Open Access 01-12-2011 | Research

Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats

Authors: Yuki Mihara, Nobuaki Egashira, Hikaru Sada, Takehiro Kawashiri, Soichiro Ushio, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi

Published in: Molecular Pain | Issue 1/2011

Login to get access

Abstract

Background

Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. The chronic neuropathy is a dose-limiting toxicity. We previously reported that repeated administration of oxaliplatin induced cold hyperalgesia in the early phase and mechanical allodynia in the late phase in rats. In the present study, we investigated the involvement of NR2B-containing N-methyl-D-aspartate (NMDA) receptors in oxaliplatin-induced mechanical allodynia in rats.

Results

Repeated administration of oxaliplatin (4 mg/kg, i.p., twice a week) caused mechanical allodynia in the fourth week, which was reversed by intrathecal injection of MK-801 (10 nmol) and memantine (1 μmol), NMDA receptor antagonists. Similarly, selective NR2B antagonists Ro25-6981 (300 nmol, i.t.) and ifenprodil (50 mg/kg, p.o.) significantly attenuated the oxaliplatin-induced pain behavior. In addition, the expression of NR2B protein and mRNA in the rat spinal cord was increased by oxaliplatin on Day 25 (late phase) but not on Day 5 (early phase). Moreover, we examined the involvement of nitric oxide synthase (NOS) as a downstream target of NMDA receptor. L-NAME, a non-selective NOS inhibitor, and 7-nitroindazole, a neuronal NOS (nNOS) inhibitor, significantly suppressed the oxaliplatin-induced pain behavior. The intensity of NADPH diaphorase staining, a histochemical marker for NOS, in the superficial layer of spinal dorsal horn was obviously increased by oxaliplatin, and this increased intensity was reversed by intrathecal injection of Ro25-6981.

Conclusion

These results indicated that spinal NR2B-containing NMDA receptors are involved in the oxaliplatin-induced mechanical allodynia.
Appendix
Available only for authorised users
Literature
1.
Yamamoto T, Yaksh TL: Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists. Pain 1992, 49: 121–128. 10.1016/0304-3959(92)90198-KPubMedCrossRef
2.
Yamamoto T, Shimoyama N, Asano H, Mizuguchi T: Time-dependent effect of morphine and time-independent effect of MK-801, an NMDA antagonist, on the thermal hyperesthesia induced by unilateral constriction injury to the sciatic nerve in the rat. Anesthesiology 1994, 80: 1311–1319. 10.1097/00000542-199406000-00019PubMedCrossRef
3.
Gaunitz C, Schüttler A, Gillen C, Allgaier C: Formalin-induced changes of NMDA receptor subunit expression in the spinal cord of the rat. Amino Acids 2002, 23: 177–182. 10.1007/s00726-001-0125-3PubMedCrossRef
4.
Ma ZL, Zhang W, Gu XP, Yang WS, Zeng YM: Effects of intrathecal injection of prednisolone acetate on expression of NR2B subunit and nNOS in spinal cord of rats after chronic compression of dorsal root ganglia. Ann Clin Lab Sci 2007, 37: 349–355.PubMed
5.
Wilson JA, Garry EM, Anderson HA, Rosie R, Colvin LA, Mitchell R, Fleetwood-Walker SM: NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists. Pain 2005, 117: 421–432. 10.1016/j.pain.2005.07.005PubMedCrossRef
6.
Zhang W, Shi CX, Gu XP, Ma ZL, Zhu W: Ifenprodil induced antinociception and decreased the expression of NR2B subunits in the dorsal horn after chronic dorsal root ganglia compression in rats. Anesth Analg 2009, 108: 1015–1020. 10.1213/ane.0b013e318193ffd2PubMedCrossRef
7.
Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, Rupniak NM: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999, 38: 611–623. 10.1016/S0028-3908(98)00218-4PubMedCrossRef
8.
Qu XX, Cai J, Li MJ, Chi YN, Liao FF, Liu FY, Wan Y, Han JS, Xing GG: Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol 2009, 215: 298–307. 10.1016/j.expneurol.2008.10.018PubMedCrossRef
9.
Nagy GG, Watanabe M, Fukaya M, Todd AJ: Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique. Eur J Neurosci 2004, 20: 3301–3312. 10.1111/j.1460-9568.2004.03798.xPubMedCrossRef
10.
Meller ST, Pechman PS, Gebhart GF, Maves TJ: Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Neuroscience 1992, 50: 7–10. 10.1016/0306-4522(92)90377-EPubMedCrossRef
11.
Cízková D, Lukácová N, Marsala M, Marsala J: Neuropathic pain is associated with alterations of nitric oxide synthase immunoreactivity and catalytic activity in dorsal root ganglia and spinal dorsal horn. Brain Res Bull 2002, 58: 161–171.PubMedCrossRef
12.
Pasetto LM, D'Andrea MR, Rossi E, Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006, 59: 159–168. 10.1016/j.critrevonc.2006.01.001PubMedCrossRef
13.
14.
Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R: Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain 2009, 147: 165–174. 10.1016/j.pain.2009.09.003PubMedCrossRef
15.
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6: 1205–1218.PubMed
16.
Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001, 85: 2293–2297.PubMed
17.
Guan Y, Yaster M, Raja SN, Tao YX: Genetic knockout and pharmacologic inhibition of neuronal nitric oxide synthase attenuate nerve injury-induced mechanical hypersensitivity in mice. Mol Pain 2007, 3: 29. 10.1186/1744-8069-3-29PubMedCentralPubMedCrossRef
18.
Abe T, Matsumura S, Katano T, Mabuchi T, Takagi K, Xu L, Yamamoto A, Hattori K, Yagi T, Watanabe M, Nakazawa T, Yamamoto T, Mishina M, Nakai Y, Ito S: Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain. Eur J Neurosci 2005, 22: 1445–1454. 10.1111/j.1460-9568.2005.04340.xPubMedCrossRef
19.
Nei K, Matsuyama S, Shuntoh H, Tanaka C: NMDA receptor activation induces glutamate release through nitric oxide synthesis in guinea pig dentate gyrus. Brain Res 1996, 728: 105–110. 10.1016/0006-8993(96)00394-0PubMedCrossRef
20.
Martin TJ, Eisenach JC: Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 2001, 299: 811–817.PubMed
21.
Gurwitz D, Weizman A: The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. Drug Discov Today 2002, 7: 403–406. 10.1016/S1359-6446(02)02242-0PubMedCrossRef
22.
Chizh BA, Headley PM: NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses. Curr Pharm Des 2005, 11: 2977–2994. 10.2174/1381612054865082PubMedCrossRef
23.
Zimmermann M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16: 109–110. 10.1016/0304-3959(83)90201-4PubMedCrossRef
24.
Egashira N, Hirakawa S, Kawashiri T, Yano T, Ikesue H, Oishi R: Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci 2010, 112: 473–6. 10.1254/jphs.10012SCPubMedCrossRef
25.
Kawashiri T, Egashira N, Watanabe H, Ikegami Y, Hirakawa S, Mihara Y, Yano T, Ikesue H, Oishi R: Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in rat model. Eur J Pain 2010, in press.
26.
Chaplan SR, Malmberg AB, Yaksh TL: Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther 1997, 280: 829–238.PubMed
27.
Chizh BA, Reissmüller E, Schlütz H, Scheede M, Haase G, Englberger W: Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil. Neuropharmacology 2001, 40: 212–220. 10.1016/S0028-3908(00)00148-9PubMedCrossRef
28.
Osborne MG, Coderre TJ: Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol 1999, 126: 1840–1846. 10.1038/sj.bjp.0702508PubMedCentralPubMedCrossRef
29.
Lau WK, Yeung CW, Lui PW, Cheung LH, Poon NT, Yung KK: Different trends in modulation of NMDAR1 and NMDAR2B gene expression in cultured cortical and hippocampal neurons after lead exposure. Brain Res 2002, 932: 10–24. 10.1016/S0006-8993(01)03395-9PubMedCrossRef
30.
Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, Minami T, Ito S: Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur J Neurosci 2003, 17: 1384–1392. 10.1046/j.1460-9568.2003.02575.xPubMedCrossRef
Metadata
Title
Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats
Authors
Yuki Mihara
Nobuaki Egashira
Hikaru Sada
Takehiro Kawashiri
Soichiro Ushio
Takahisa Yano
Hiroaki Ikesue
Ryozo Oishi
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Pain / Issue 1/2011
Electronic ISSN: 1744-8069
DOI
https://doi.org/10.1186/1744-8069-7-8

Other articles of this Issue 1/2011

Molecular Pain 1/2011 Go to the issue

Research

Specific involvement of atypical PKCζ/PKMζ in spinal persistent nociceptive processing following peripheral inflammation in rat

Short report

Homer1a signaling in the amygdala counteracts pain-related synaptic plasticity, mGluR1 function and pain behaviors

Research

Neural correlates of heterotopic facilitation induced after high frequency electrical stimulation of nociceptive pathways

Research

Nav1.7 is the predominant sodium channel in rodent olfactory sensory neurons

Research

Neuropathic Nav1.3-mediated sensitization to P2X activation is regulated by protein kinase C

Research

Dynorphin is expressed primarily by GABAergic neurons that contain galanin in the rat dorsal horn